Livzon Pharmaceutical Group Inc. announced a proposal to elect Ms. Wang Zhiyao as an independent non-executive director for the eleventh session of its Board. The appointment is intended to fill the vacancies arising from the scheduled retirements of two current independent non-executive directors, whose six-year tenures are about to expire.

The appointment of Ms. Wang is contingent upon shareholder approval at the Company’s 2025 first extraordinary general meeting (EGM) and also depends on no objection from the Shenzhen Stock Exchange after its standard filing and review process. Her term will begin on the date of the EGM’s approval and will conclude at the end of the eleventh session of the Board.

Ms. Wang, aged 39, has degrees in Clinical Medicine from Xi'an Jiaotong University, Public Administration from Renmin University of China, and Finance from Harvard University. She has previously worked for several pharmaceutical and biotechnology ventures and is currently pursuing a Doctor of Philosophy in Biomedical Sciences at The University of Hong Kong. She has confirmed her independence in accordance with Rule 3.13 of the Hong Kong Listing Rules.

Upon assuming directorship, Ms. Wang will receive an annual fee of RMB120,000 before tax, determined with reference to her duties and responsibilities within the Company and to the prevailing market standards. The Company states there are no other matters warranting additional shareholder attention, and no further particulars require disclosure under relevant Hong Kong Listing Rules stipulations.